---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058675"
form_type: "8-K"
ticker: null
cik: "0001082038"
company_name: "DURECT CORP"
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T01:53:46.324178+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DURECT reports Q1 net loss $7.6M; FDA supports single pivotal trial for larsucosterol in AH

## Summary
- FDA feedback supports single pivotal Phase 3 trial for larsucosterol in alcohol-associated hepatitis; NDA filing possible if successful.
- Q1 2024 total revenues $1.8M, net loss $7.6M vs revenues $2.1M, net loss $12.0M in Q1 2023.
- Cash and investments $21.6M at Mar 31, 2024, down from $29.8M at Dec 31, 2023; debt $14.6M.
- Late-breaking oral presentation of AHFIRM Phase 2b data accepted at EASL Congress 2024 in June.

## SEC filing metadata
- accession: 0000950170-24-058675
- form_type: 8-K
- cik: 0001082038
- company_name: DURECT CORP
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082038/000095017024058675/0000950170-24-058675-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082038/000095017024058675/drrx-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058675
- JSON: https://secwatch.observer/filing/0000950170-24-058675.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058675.txt

## Key facts
- Earnings Releases
  DURECT CORP reported three months ended March 31, 2024 results: revenue $1.8 million, net income $7.6 million.
  - Period: three months ended March 31, 2024
  - Revenue: $1.8 million
  - Net income: $7.6 million
  - Result: reported results
  source text: 2b AHFIRM trial, which evaluated the safety and efficacy of larsucosterol as a treatment for patients with severe AH. Financial Highlights for Q1 2024: • Total revenues were $1.8 million and net loss was $7.6 million for the three months ended March 31, 2024 compared to total revenues of $2.1 million and net loss of $12.0 million for the three months ended March
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082038/000095017024058675/0000950170-24-058675-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.